Ajaz Saima, Chamley Mark, Lok James, Soliman Riham, Khan Reece, Ahir Karan, Curtis Monique, Guerra-Veloz María Fernanda, Agarwal Kosh
Institute of Liver Disease, Kings College Hospital, Denmark Hill, London SE5 9RS, UK.
North Wood Group Practice Clinical Lead, Lambeth Diabetes Intermediate Care Team, London, UK.
Ther Adv Chronic Dis. 2024 Jul 30;15:20406223241264539. doi: 10.1177/20406223241264539. eCollection 2024.
Metabolic associated fatty liver disease (MAFLD) stands as the leading cause of chronic liver disease globally. Notably, individuals with metabolic risk factors, such as diabetes and obesity, exhibit a staggering prevalence of MAFLD, with estimates reaching up to 70%. However, despite its widespread occurrence, there's a noticeable gap in understanding and awareness about MAFLD among these high-risk groups.
The main objective of this study was to assess the awareness and prevalence of MAFLD among diabetic patients who regularly receive secondary care focusing particularly on how multiethnic backgrounds and associated lifestyle preferences influence these health outcomes.
Cross-sectional study.
Patients with type 2 diabetes (T2D) who regularly attend Lambeth Diabetes Intermediate Care Team clinics were invited to undergo MAFLD screening using FibroScan. Those who agreed to participate were provided with structured questionnaires on diet, physical activity, and MAFLD knowledge by a hepatologist. For each participant, anthropometric data, medical history, liver stiffness measurement, and controlled attenuation parameter (CAP) were documented. Steatosis was identified with a CAP value of ⩾275 dB/m, and advanced fibrosis was flagged at values of ⩾8 kPa.
The FibroScan data was valid in 96.4% (215), 53.5% (115/215) had steatosis and 26.2% (58/215) had liver fibrosis in this multiethnic high-risk group. Awareness of MAFLD was notably low at 30.9%. Alarmingly, 69% of patients diagnosed with liver fibrosis were unfamiliar with the condition. Additionally, understanding of MAFLD showed variation among different ethnic groups with highest levels were demonstrated in the Caucasian/White population (46%). Majority (96%) of these subjects were receiving specific lifestyle advice from healthcare professionals due to metabolic conditions and comorbidities. However, most patients preferred diets that were rich in carbohydrates (65.8%) and only 43% subjects performed moderate exercise daily highlighting lack of understanding regarding MAFLD and lifestyle management.
There's a pressing need for increased awareness of MAFLD, especially in multiethnic high-risk groups. Additionally, the development of cost-effective strategies to stratify risk is essential to address this growing health concern.
代谢相关脂肪性肝病(MAFLD)是全球慢性肝病的主要病因。值得注意的是,患有糖尿病和肥胖症等代谢风险因素的个体中,MAFLD的患病率惊人,估计高达70%。然而,尽管MAFLD普遍存在,但这些高危人群对其的理解和认知仍存在明显差距。
本研究的主要目的是评估在接受二级护理的糖尿病患者中MAFLD的认知度和患病率,特别关注多民族背景和相关生活方式偏好如何影响这些健康结果。
横断面研究。
邀请定期前往兰贝斯糖尿病中级护理团队诊所的2型糖尿病(T2D)患者使用FibroScan进行MAFLD筛查。同意参与的患者由肝病专家提供关于饮食、体育活动和MAFLD知识的结构化问卷。记录每位参与者的人体测量数据、病史、肝脏硬度测量值和受控衰减参数(CAP)。CAP值≥275 dB/m时确定为脂肪变性,≥8 kPa时标记为进展性肝纤维化。
在这个多民族高危人群中,FibroScan数据在96.4%(215例)中有效,53.5%(115/215)有脂肪变性,26.2%(58/215)有肝纤维化。MAFLD的认知度极低,仅为30.9%。令人担忧的是,69%被诊断为肝纤维化的患者对该疾病并不了解。此外,不同种族群体对MAFLD的理解存在差异,白种人/白人人群的认知水平最高(46%)。这些受试者中的大多数(96%)因代谢状况和合并症而接受医疗保健专业人员提供的特定生活方式建议。然而,大多数患者更喜欢富含碳水化合物的饮食(65.8%),只有43%的受试者每天进行适度运动,这突出表明对MAFLD和生活方式管理缺乏了解。
迫切需要提高对MAFLD的认识,尤其是在多民族高危人群中。此外,制定具有成本效益的风险分层策略对于解决这一日益严重的健康问题至关重要。